ArticleNeurology. Clinical practice2016

Comparative efficacy of first-line natalizumab vs IFN-β or glatiramer acetate in relapsing MS.

Tim Spelman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.